Bifidobacterium infantis M-63

Bifidobacterium infantis M-63 is a specific probiotic strain that colonizes the infant gut and modulates immune responses by producing short-chain fatty acids and competing with pathogenic bacteria for epithelial binding sites. Its primary mechanism involves downregulating NF-κB-mediated inflammatory signaling, thereby reducing proinflammatory cytokines such as IL-6 and TNF-α in the neonatal gastrointestinal tract.

Origin & History

Bifidobacterium infantis M-63 is a specific strain of gram-positive, anaerobic bacteria naturally found in the human infant gut microbiota, isolated and cultured for use as a probiotic supplement. This strain is produced through controlled fermentation and delivered as lyophilized (freeze-dried) cells in powder or sachet form at specified colony-forming unit (CFU) concentrations.

Historical & Cultural Context

B. infantis M-63 has no traditional medicine history as it is a modern clinical isolate developed through contemporary microbiological research. The strain was specifically selected and developed based on scientific understanding of beneficial infant gut microbiota composition.

Health Benefits

• Reduces infant gut inflammation: Significantly decreased proinflammatory cytokines and calprotectin levels in a randomized controlled trial of 111 infants (PMID: 40681696)
• Improves gastrointestinal function: Reduced vomiting, constipation, and flatulence in formula-fed infants in a multicenter RCT of 66 infants (PMID: 28270216)
• Alleviates allergic rhinitis symptoms: Significant improvement in symptoms and quality of life in 40 children in a placebo-controlled trial (p < 0.005) (PMID: 28270216)
• Enhances mental well-being in IBS: Improved anxiety and bodily pain scores in 20 IBS patients after 3 months supplementation (p = 0.04) (PMID: 30525951)
• Establishes beneficial gut microbiota: Increases Bifidobacterium abundance while reducing pathogenic Enterobacteriaceae in multiple infant studies

How It Works

B. infantis M-63 colonizes the infant intestinal epithelium and suppresses NF-κB activation, reducing transcription of proinflammatory cytokines including IL-6, IL-8, and TNF-α while lowering fecal calprotectin, a biomarker of intestinal inflammation. The strain produces acetate and lactate through fermentation of human milk oligosaccharides (HMOs), acidifying the gut lumen and inhibiting colonization by pathogenic Enterobacteriaceae. Additionally, it upregulates tight-junction proteins such as occludin and claudin-1, strengthening the intestinal epithelial barrier and reducing paracellular permeability.

Scientific Research

Multiple randomized controlled trials demonstrate B. infantis M-63's efficacy, including a study of 111 healthy infants showing anti-inflammatory effects (PMID: 40681696) and a multicenter RCT of 66 formula-fed infants demonstrating reduced gastrointestinal issues (PMID: 28270216). A controlled trial in 20 IBS patients revealed improvements in mental well-being and anxiety (PMID: 30525951), while ongoing trials are investigating prevention of type 1 diabetes and atopic dermatitis.

Clinical Summary

A randomized controlled trial of 111 infants (PMID: 40681696) demonstrated that B. infantis M-63 supplementation significantly decreased proinflammatory cytokines and fecal calprotectin levels compared to placebo, providing strong evidence for its anti-inflammatory effects in the neonatal gut. A separate multicenter randomized trial in formula-fed infants showed clinically meaningful reductions in vomiting, constipation, and flatulence, suggesting improved gastrointestinal motility and comfort. Evidence is currently limited to infants and neonates, with most trials using strain-specific preparations; extrapolation to older populations or different Bifidobacterium strains is not supported by current data. Overall, the evidence base is promising but still emerging, with larger and longer-duration trials needed to confirm optimal dosing and long-term safety.

Nutritional Profile

Bifidobacterium infantis M-63 is a live probiotic microorganism, not a conventional food ingredient, and thus does not contribute macronutrients (protein, fat, carbohydrates) or micronutrients in meaningful dietary quantities. Key bioactive components include: (1) Cell wall constituents — peptidoglycan and lipoteichoic acid fragments that interact with host Toll-like receptors (TLR-2, TLR-4), modulating innate immune signaling; (2) Exopolysaccharides (EPS) — strain-specific surface polysaccharides that facilitate gut epithelial adhesion and immunomodulation; (3) Short-chain fatty acids (SCFAs) — fermentation metabolites including acetate as the primary end-product of bifidobacterial metabolism, with minor amounts of lactate, contributing to luminal pH reduction and colonocyte energy substrate; (4) B-vitamins — Bifidobacterium species are known producers of folate (B9) and riboflavin (B2) in nanogram-per-mL culture concentrations, though quantitative data specific to M-63 strain in vivo is limited; (5) Bacteriocin-like inhibitory substances (BLIS) — antimicrobial peptides produced at trace levels that suppress pathogenic competitors; (6) Indole derivatives and tryptophan metabolites — produced via gut microbiome cross-talk, supporting aryl hydrocarbon receptor (AhR) signaling relevant to immune tolerance. Typical commercial delivery dose is 1×10^8 to 1×10^9 CFU per serving. Bioavailability note: Viability through gastric acid and bile salts is strain-dependent; M-63 demonstrates moderate acid tolerance, and encapsulation or inclusion in formula matrix improves survival to the target intestinal site.

Preparation & Dosage

Clinically studied dosages include: 1.0 × 10⁹ CFU daily for healthy infants from day 7 to 3 months of age; 10⁷-10⁹ CFU daily for formula-fed infants; 1.0 × 10⁹ CFU daily for 3 months in IBS patients; and 140 million CFU/g when enriched in infant formula. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Lactobacillus rhamnosus LCS-742, Bifidobacterium longum BB536, Bifidobacterium breve M-16V, Human Milk Oligosaccharides (HMOs), Acacia fiber

Safety & Interactions

B. infantis M-63 is generally considered safe for healthy term and near-term infants, with clinical trials reporting no serious adverse events attributable to the strain. In immunocompromised individuals, including premature neonates with very low birth weight, live probiotic administration carries a theoretical risk of bacteremia or sepsis, and use in these populations should be discussed with a physician. No significant drug interactions have been formally documented, though concurrent antibiotic use would be expected to reduce strain viability and diminish efficacy. Pregnancy and lactation safety data specific to this strain are not established; maternal supplementation studies are lacking and should be approached cautiously without medical guidance.